Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial
Primary result · Change in energy intake during ad libitum lunchResult — go to the resultEstimated treatment difference −524.6 kcal 95% CI −648.1 to −401.0Authors' conclusion
Our results suggest tirzepatide reduces food intake, potentially by impacting ingestive behavior.
Study context
- Population
- Adults without diabetes, BMI 27–50 kg/m² (overweight or obesity)
- Participants
- 114 adults
- Comparison
- Once-weekly tirzepatide vs placebo
- Primary endpoint
- Change from baseline in energy intake during an ad libitum lunch, tirzepatide vs placebo
- Follow-up
- Week 3
Methodological detailsphase 1, blinded tirzepatide and placebo, open-label liraglutide, randomized 1:1:1
- Phase 1
- Blinded tirzepatide and placebo
- Open-label liraglutide
- Randomized 1:1:1
Primary result
Change in energy intake during ad libitum lunch
Estimated treatment difference
−524.6 kcal
95% CI −648.1 to −401.0
P < 0.0001
Tirzepatidevs Placebo
estimated treatment difference −524.6 kcal (95% CI −648.1 to −401.0); P < 0.0001
As reported in the abstract
Secondary outcomes
Self-reported ingestive behavior
- Tirzepatide decreased overall appetite, food cravings, tendency to overeat, perceived hunger and reactivity to foods in the environment vs placebo
- No impact on volitional restriction of dietary intake vs placebo
BOLD fMRI activation to food photos · week 3
- No statistically significant impact on activation to highly palatable food photos (aggregated high-fat, high-sugar and high-fat, high-carbohydrate) vs placebo
- Decreased activation to high-fat, high-sugar food photos in medial frontal and cingulate gyri, orbitofrontal cortex and hippocampus vs placebo
Original publication
Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. Published 24 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →